Symphonix Plans Vibrant SoundBridge Postmarket Surveillance Study
This article was originally published in The Gray Sheet
Executive Summary
Symphonix Devices will conduct an 18-month postmarket surveillance study of patients implanted with the Vibrant P and Vibrant D Soundbridge implantable middle-ear hearing devices. FDA approved the products on Aug. 31.